{"a":[{"_":"Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon","$":{"href":"/biotech/cellectis-cans-allogeneic-car-ts-hop-aboard-vivo-bandwagon","hreflang":"en"}}]}

Summary

Cellectis is discontinuing its allogeneic CAR-T program to focus on in vivo CAR-T approaches, reflecting a broader industry shift away from allogeneic cell therapies toward in vivo platforms.